LincRNA-p21调控PI3K/AKT信号通路逆转结肠癌细胞伊立替康耐药性

图5 LincRNA-p21对PI3K/AKT通路的调控作用(n = 3). A: si-lincRNA-p21转染后, Western blot检测HCT-8/CPT-11细胞中p-PI3K、PI3K、p-AKT和AKT的蛋白表达, 与si-NC组比较, ^aP = 0.000, ^bP = 0.002; B: si-lincRNA-p21转染后, Western blot检测SW480/CPT-11细胞中p-PI3K、PI3K、p-AKT和AKT的蛋白表达, 与si-NC组比较, ^cP = 0.000, ^dP = 0.015; C: pcDNA-lincRNA-p21转染后, Western blot检测HCT-8/CPT-11细胞中p-PI3K、PI3K、p-AKT和AKT的蛋白表达, 与pcDNA-vector组比较, ^eP = 0.006, ^fP = 0.003; D: pcDNA-lincRNA-p21转染后, Western blot检测SW480/CPT-11细胞中p-PI3K、PI3K、p-AKT和AKT的蛋白表达, 与pcDNA-vector组比较, ^gP = 0.004, ^hP = 0.001. lincRNA-p21: 长链基因间非编码RNA-p21; CPT-11: 伊立替康; PI3K: 磷脂酰肌醇3-激酶; p-PI3K: 磷酸化PI3K; AKT: 蛋白激酶B; p-AKT: 磷酸化AKT.